Consumer Health Results Roundup: Genomma, Ipsen And Taisho

Mexico's Genomma enjoys good growth in the second quarter, while Japan's Taisho records a steady start to its new financial year. Meanwhile, France's Ipsen endures a difficult period as its biggest OTC brand falters.

Red and blue arrow elevators with businessmen going up and down.

Mexico’s Genomma Lab Internacional SAB de CV reported OTC sales up by 7.5% to MXN1.48bn ($75.4m) in the second quarter, as turnover improved at single-digit rates in all three of its reporting regions.

In Genomma’s largest reporting region by turnover, Mexico, the firm posted OTC sales up by 7

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business

Mitigating Tariff Impacts, Kenvue Adjusts Outlook

 

“The situation has evolved considerably” since Kenvue gave its initial full-year outlook in February, “and remains quite fluid,” says president and CEO Thibaut Mongon as firm reports Q1 net sales decreasing 3.9% to $3.7bn

Looming Tariffs Give Boost To Latest PCH Results While Cutting Costs In Response Takes Priority

 

Looming imposition of tariffs by Trump on imports from most every country had an influence on consumers during the January-March period, particularly on online shopping. Increasing product prices on the table, “but our efforts are going to start with cost savings,” says CFO Christine Sacco.

Danes Get OTC Access To ED Treatment

 
• By 

Navamedic has launched Eroxon in Danish pharmacies giving men in the country OTC access to an ED treatment for the first time.